Foghorn therapeutics announces first patient dosed with first-in-class oral smarca2 selective inhibitor fhd-909 in a phase 1 trial for smarca4 mutated solid tumors

Primary target patient population for the fhd-909 phase 1 trial is  non-small cell lung cancer (nsclc) lilly leads the clinical development of the phase 1 trial foghorn's selective smarca2 oncology program is part of a u.s. 50/50 co-development and co-commercialization collaboration with lilly cambridge, mass., oct. 10, 2024 (globe newswire) -- october 10, 2024 -- foghorn® therapeutics inc. (nasdaq: fhtx), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that the first patient has been dosed with fhd-909 (ly4050784) in the phase 1 trial for smarca4 (brg1) mutated cancers, with non-small cell lung cancer (nsclc) as the primary target patient population.
FHTX Ratings Summary
FHTX Quant Ranking